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Background: Tuberculosis (TB) is the most common co infection in HIV-infected persons in India, requiring
concomitant administration of anti TB and antiretroviral therapies. Paradoxical worsening of tuberculosis after
anti-retroviral therapy (ART) initiation is frequently seen.
Objective: To study the frequency, clinical presentation and outcome of paradoxical tuberculosis associated
immune reconstitution inflammatory syndrome (TB-IRIS) in HIV infected patients in a TB hospital in North India.
Design: A retrospective chart review of HIV-infected TB patients on anti-tubercular treatment (ATT) at time of ART
initiation over a 3 year period. Medical records were reviewed for clinical manifestations and outcome in patients
who developed TB-IRIS.
Results: 514 HIV-infected patients were enrolled between January 2006 and December 2008. Thirteen (12.6%) of
103 patients who had received ART and ATT simultaneously developed paradoxical TB-IRIS. Clinical presentations of
paradoxical TB-IRIS included new lymphadenopathy (n = 3), increase in size of existing lymphadenopathy (n = 3),
worsening of existing pulmonary lesions (n = 2), appearance of new pleural effusion (n = 1) and prolonged high
grade fever (n = 2). Four patients developed new tubercular meningitis as manifestation of TB-IRIS. Our cases
developed TB-IRIS a median of 15 days after starting ART (IQR 15–36). TB-IRIS patients were older (> 35 years) than
those with no IRIS (P = 0.03), but were not distinguishable by CD4 T-cell count, duration of ATT before ART or the
outcome of TB treatment. Eight (62%) patients had a complete recovery while 5 (38%) patients with TB-IRIS died, of
which majority (n = 3) had meningitis.
Conclusions: Paradoxical TB-IRIS is a frequent problem during concomitant ATT and ART in HIV-TB co infected
patients in north India. Meningitis is a potentially life threatening manifestation of TB-IRIS.
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Tuberculosis (TB) is the most common co-infection in
HIV-infected persons in high burden countries like India
[1]. Many HIV patients consequently require concomi-
tant anti-tubercular treatment (ATT) and antiretroviral
therapy (ART). Paradoxical worsening of TB after ART ini-
tiation is termed as TB associated immune reconstitution* Correspondence: upasna.ag @gmail.com
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reproduction in any medium, provided the orinflammatory syndrome (TB-IRIS) as these exaggerated in-
flammatory responses are attributed to immune recovery.
TB-IRIS is characterized by either deterioration of existing
lesions (paradoxical TB-IRIS) or the appearance of new
disease associated with previously subclinical infection
(unmasking TB-IRIS) after ART initiation [2]. These condi-
tions probably reflect rapid restoration of pathogen-specific
immune responses with ART.
Paradoxical TB-IRIS has varied clinical presentations.
In some cases, it may present as mild lymph node
inflammation alone, while in others it may manifest asl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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or acute respiratory distress syndrome [3]. In a clinical
setting, paradoxical TB-IRIS needs to be differentiated
from other complications of ART and HIV infection like
drug toxicities, development of new opportunistic infec-
tion, failure of treatment and possible non-adherence to
treatment. In this paper, we have evaluated the fre-
quency, clinical presentation and outcome of paradoxical
TB-IRIS in patients attending an HIV clinic in a referral
TB hospital in North India.
Methods
This study was a retrospective analysis of prospectively
collected data obtained in a structured format from
patients with HIV infection and TB disease who were on
ATT at time of ART initiation. Detailed case notes were
available until the end of ATT, so occurrence of IRIS
episode and the time of IRIS development could be
accurately analysed.
Patient selection
We reviewed structured patient charts for 103 adult
HIV-infected patients, who had active TB and were trea-
ted for tuberculosis and HIV disease at the HIV clinic of
LRS Institute of TB and Respiratory Diseases, New Delhi,
between January 2006 and December 2008.
All patients included for this analysis were adults, had
active TB at entry to HIV care at the clinic and were
started on ATT as soon as TB was diagnosed. None of
them were on antiretroviral therapy at time of TB diagno-
sis. Baseline (pre-ART) CD4 T-cell counts were done and
combination antiretroviral therapy was initiated during
ATT, as soon as patient stabilized on ATT, as per the
National ART guidelines [4]. Data till outcome of TB
treatment was available. Follow-up period till completion
of TB treatment was taken for the analysis as TB-IRIS
occurs during concomitant TB and ART. End points were
defined as occurrence of TB-IRIS, completion of ATT or
death/default while on TB treatment. HIV-TB cases who
died or defaulted while on ATT alone and could not be
initiated on ART were excluded. IRIS episodes not asso-
ciated with M. tuberculosis infection were not considered
in this analysis.
Diagnosis and treatment of TB
TB was diagnosed as per existing WHO and Revised
National Tuberculosis Control Program (RNTCP) [5]
guidelines by identification of typical clinical features,
isolation of acid fast bacilli (AFB) from a clinical specimen
wherever possible, radiological findings and decision to
treat for TB. TB was classified either as smear-positive
pulmonary TB, smear-negative pulmonary TB, or extra-
pulmonary TB. Investigations available for patients included
sputum smear microscopy for AFB, mycobacterial cultureand drug sensitivity, chest radiology, abdominal ultra-
sonography, fine needle aspiration for cytology, AFB
smear / culture and computed tomography wherever indi-
cated. ATT comprised standard short course regimens
available under the RNTCP which consist of rifampicin,
isoniazid, pyrazinamide and ethambutol with additional
streptomycin in retreatment cases. Outcomes of TB treat-
ment also had been recorded in accordance to the RNTCP
guidelines as Cured, Treatment completed, Died, Failure
and Defaulted [5].
Diagnosis of HIV and antiretroviral therapy
HIV infection was diagnosed using three antigenically
different rapid kits as per the national HIV testing
policy. ART regimens followed WHO and National ART
Program guidelines [4] and comprised efavirenz in com-
bination with either zidovudine or stavudine and lamivu-
dine; the dose of efavirenz for all adult HIV infected
patients on ATT co-prescription being 600 mg once a
day, in accordance to the national guidelines. CD4 cell
counts were determined by flow-cytometry technique
using Facs Count machine with Facscount™ reagents
(Becton Dickinson, USA). As per Program guidelines,
CD4 T cell counts were determined before treatment
initiation and every six months thereafter. Plasma HIV
viral load testing is not available under the Program for
patients on first line ART regimens.
Diagnosis and management of paradoxical TB-IRIS
The paradoxical TB-IRIS cases documented in the
records were diagnosed at the time as an initial symptom-
atic improvement during ATT followed by an exacerba-
tion of symptoms, signs or radiological manifestations of
TB after initiation of ART, which was not due to another
opportunistic infection, drug adverse effect or ineffective
TB treatment [6]. TB–IRIS cases had been diagnosed at
the time of presentation of symptoms by a concurrence of
opinion of two trained HIV physicians, after exclusion of
other causes. Sputum samples of patients who developed
pulmonary manifestations of TB-IRIS were sent for AFB
culture and sensitivity testing to exclude drug resistant
TB. Cases manifesting CNS symptoms had undergone
cerebrospinal fluid examination – cytology, biochemical
analysis, India ink preparation and smear/culture for AFB.
Contrast enhanced CT scans of the brain though not rou-
tinely done, were available for all 4 cases with CNS symp-
toms. TB-IRIS episodes were managed with non-steroidal
anti- inflammatory drugs (NSAIDS) and/or steroids, in
addition to ATT and ART. Serious cases received in-
patient care.
At time of this analysis, the paradoxical TB-IRIS cases
documented in the records were also compared to the
International Network for the Study of HIV-associated IRIS
(INSHI) case definition for paradoxical TB-associated IRIS
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13 cases conformed to the criteria recommended by
INSHI for paradoxical TB-IRIS. However all criteria could
not be met in 3 cases. In one case, the time of occurrence
of TB-IRIS was nearly four months as compared to three
months specified in the INSHI definitions and in the other
two, high grade protracted fever was the only manifest-
ation of IRIS.
This study was approved by the Institutional Review
Board of LRS Institute of TB and Respiratory Diseases,
New Delhi, an autonomous institute under the Ministry
of Health and Family Welfare, GOI.
Data analysis
Continuous data are presented as median and interquar-
tile range (due to extreme values). Due to small sample
size, the continuous variables were compared using
Mann–Whitney non parametric statistics. Proportions of
categorical variables were compared using chi – squared
test (univariate analysis). Yates correction was applied
for cells with expected frequency less than 5. All tests
were 2-tailed and p <0.05 was considered statistically
significant.
Results
A total of 514 HIV-infected patients were registered at
the HIV clinic of LRS Institute of TB and Respiratory
Diseases, New Delhi between January 2006 and December
2008. Of these, 103 patients had received ART and ATT
simultaneously and met our inclusion criteria.
Thirteen patients (12.6%) developed worsening of pre-
existing disease and were considered to have experienced
paradoxical TB-IRIS. Details of patients developing para-
doxical TB-IRIS are summarised in Table 1. Paradoxical
IRIS manifested as new lymphadenopathy in 3 (23%), in-
crease in size of existing lymphadenopathy in 3 (23%),
worsening of existing pulmonary lesions in 2 (15%), and
new pleural effusion in 1(8%) of the TB-IRIS cases. Four
(31%) patients developed tuberculous meningitis after ini-
tiation of ART. Two of the four patients who developed
meningitis presented with severe headache and vomiting.
The other two presented with altered sensorium, one of
whom also developed fever. Neck rigidity was present in
all four cases. Cerebrospinal fluid examination was done
in all four cases. CSF examination revealed lymphocytosis
with elevated protein and reduced glucose levels. None of
the four cases showed any fungal growth on India Ink
staining of the CSF. In the two cases where CSF cultures
were done, cultures for AFB and fungal elements were
negative. Available CT scans (head) showed features sug-
gestive of mild hydrocephalous in one, basal exudates in
one and reported no abnormality in 2 cases. None of the
CT scans revealed any space occupying lesion. In 2 (15%)
patients, a recurrence of fever was the only manifestationof IRIS. Fever was continuous, high grade (>39.4° C) and
lasted for 1 and 3 weeks. No other cause for this fever
was found. Both cases were managed by NSAIDS with
continued ATT and ART.
Six patients (47%) received out-patient care and seven
(54%) required hospitalization. Nine patients (69%)
required steroids as they had severe disease manifestations
including meningitis, worsening of extensive pulmonary
disease and compressive lymphadenopathy. Three patients
were prescribed solely NSAIDS. One required surgical
drainage of a lymph node abscess.
Eight (62%) of the 13 patients with paradoxical TB-IRIS
had a complete recovery while 5 (38%) patients died.
Deaths were attributable to meningitis in 3 patients
and extensive worsening of bilateral pulmonary infiltrates
in the other 2. All five had been hospitalized and started
on steroids. The mean CD4 T cell count for the five cases
that died was 73 cells/μl (median 25, IQR 41–74). The
means of CD4 cell counts of the three meningitis patients
and the other two cases that died were 99 cells/μl and 34
cells/μl respectively.
Demographic and clinical factors associated with IRIS
in earlier studies were analysed in patients with and
without IRIS (Table 2). No differences in baseline CD4
T-cell count or CD4 T-cell recovery on ART were evi-
dent in the two groups. TB-IRIS patients were a little
older (> 35 years) than those with no IRIS (P = 0.03).
They had received ATT for a shorter interval before
ART initiation (27 days vs. 42 days) but this difference
was not statistically significant. The outcome of treat-
ment of TB was available in all the cases (Table 2). The
success of TB treatment (cured and treatment completed
cases) was similar in patients who developed TB-IRIS
and those who did not. The proportion of deaths was
higher in patients who developed TB-IRIS, however this
difference was not found to be statistically significant
(P = 0.08).
Discussion
Paradoxical TB-IRIS is a clinical entity frequently
encountered when ART is initiated in HIV and TB co-
infected patients. Understanding of this phenomenon is
particularly relevant for HIV clinics in South East Asia
and Africa where many patients with active TB enter
ART programs [1,7].
Retrospective and prospective studies have reported
that 7- 43% of patients with HIV-TB co-infection de-
velop IRIS [3]. The frequency of TB-IRIS among patients
starting ART during ATT in our series (12.6%) is within
this range. Our cases developed IRIS a median of 15 days
after starting ART (IQR 15–36) (Table 2), which is simi-
lar to that reported by other authors. In most patients,
TB-IRIS is seen to develop within the first 2–6 weeks
[3,7-10], though symptoms can occur as early as five
























1 26 Male 110 Pulmonary TB with mediastinal
lymphadenopathy
18 Increase in size of mediastinal lymph




2 45 Male 6 Bilateral pulmonary TB 127 Painful new abdominal
lymphadenopathy (Baseline USG
abdomen was normal)
15 Yes Steroids Recovered
3 39 Male 106 Mediastinal lymphadenopathy 176 Severe headache, neck rigidity, TB
meningitis
17 Yes Steroids Recovered
4 39 Male 41 Miliary TB with pleural effusion
and hilar and cervical
lymphadenopathy
14 Altered sensorium, neck rigidity, TB
meningitis
30 Yes Steroids Died





6 35 Male 106 Pulmonary TB 25 Recurrence of fever (high grade,
prolonged)
7 No NSAIDS Recovered
7 38 Male 14 Bilateral pulmonary TB with
empyema and abdominal
lymphadenopathy
37 Increased bilateral pulmonary
infiltrates
39 Yes Steroids Died
8 44 Male 167 Cervical lymphadenopathy 22 Increase in size of existing cervical
lymph node, appearance of new
cervical lymph node
6 No Steroids Recovered
9 51 Male 62 Pulmonary TB with abdominal
lymphadenopathy
29 New inguinal lymph node 48 No NSAIDS Recovered
10 46 Male 181 Miliary TB 26 Severe headache, vomiting, TB
meningitis
36 Yes Steroids Died
11 30 Male 74 Extensive bilateral pulmonary TB 27 Fever, altered sensorium, TB
Meningitis
120 Yes Steroids Died
12 50 Male 56 Mediastinal lymphadenopathy 22 Recurrence of fever (high grade,
prolonged)
12 No NSAIDS Recovered
13 38 Male 55 Pulmonary TB with pleural
effusion
52 Increased bilateral pulmonary
infiltrates




















Table 2 Comparison of patient characteristics and outcome of TB treatment in cases with and without paradoxical TB
–IRIS (univariate analysis)
Cases with TB-IRIS (n = 13) Cases without TB-IRIS (n = 90) p value
Patient characteristics
Age, in years 39 [35–45]* 32 [28–39]* 0.03
Age> 35 years, n (%) 9 (69%) 30 (33%) 0.03
Baseline CD4 T-cell count (cells/μl) 74 [55–110]* 84 [46–142]* 0.52
CD4 T cell count at six months on ART (cells/μl) 142[192–467]* (n = 7) 156 [176–423]* (n = 66) 0.85
Male gender, n (%) 13 (100%) 76 (84%) 0.27
Disseminated & extra pulmonary TB, n (%) 10 (77%) 57(63%) 0.54
Interval between ATT and ART initiation, in days 27 [22–52]* 42 [25–97]* 0.30
Interval between ART initiation and appearance of IRIS, in days 15 [12–36]* Not applicable
Outcome of TB treatment
Successfully treated, n (%) (Bacteriologically Cured & TB Treatment
Completed cases)
8 (61.5%) 70 (77.8%) 0.35
Treatment failures, n (%) (Bacteriologically positive at five or more
months of TB treatment)
0 2 (2.2%) 0.59
Died, n (%) (Death during course of TB treatment) 5 (38.5%) 13 (14.4%) 0.08
Defaulted, n (%) (TB treatment discontinued for 2 or more months
consecutively after initiation)
0 5 (5.6%) 0.87
*median [Inter quartile range].
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opment of TB-IRIS after the first three months of ART
initiation are infrequent [11].
Baseline CD4 T cell counts or CD4 T cell recovery
after six months of ART were not different between
patients who developed TB-IRIS and those who did not.
Earlier studies from South India [9] and Thailand [12]
report similar findings. However, there are cohort stud-
ies from South Africa [7,13] which report a definite asso-
ciation of development of TB-IRIS with low baseline
CD4 counts. The reason for this difference is not clear.
It may be a reflection of the overall low CD4 counts of
the cohort of HIV-TB cases in this analysis.
In our study from North India, we report serious
neurologic and pulmonary manifestations of IRIS, with
poor outcomes in patients with extensive and dissemi-
nated disease. Neurological disease following initiation
of ART due to inflammation associated with previously
subclinical M. tuberculosis infection in the central ner-
vous system (CNS) is of particular concern [2]. In this
study, we report 4 cases (31%) of meningitis TB-IRIS.
They were receiving ATT for extensive TB disease, but
had no evidence of CNS involvement at time ART initi-
ation. Following development of meningitis, all four
patients were hospitalized and received steroids, but
three died. The mean CD4 cell count of three meningitis
patients who died was higher as compared to the other
two paradoxical TB IRIS patients who died (99 vs.34
cells/μl). The published literature on CNS TB IRIS is
mostly restricted to a few case reports [14,15]. A recentprospective case series from South Africa by Pepper et
al, with a larger sample size (190 cases of TB IRIS) has
reported neurologic TB-IRIS in 23 (12%) cases where
also meningitis was the most common manifestation,
followed by tuberculoma and myeloradiculopathy. In
their study, Pepper et al also describe a low (70%) six
month survival for neurologic TB-IRIS cases [16].
Working under program conditions, our study was
limited by non-availability of plasma viral loads. Also the
sample size was inadequate to define risk factors for TB
IRIS or draw statistical inferences in general. However it
is a precise retrospective review of data, especially out-
come data, from a referral TB hospital which cares for
TB patients referred from all over north India.
In conclusion, similar to other regions of the world,
paradoxical TB-IRIS is a frequent problem during con-
comitant ATT and ART in HIV-TB co infected patients
from northern India and mostly occurs during the initial
weeks of ART. Meningitis is a potentially life threatening
manifestation of TB-IRIS. Future studies in areas with
high prevalence of M. tuberculosis infection should there-
fore address the issue of how patients at risk of developing
paradoxical CNS TB-IRIS might be identified.
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